GlassScriptPhysician profile
Tomas Vasiliauskas
NPI 1073612529
$7,791.69
in general payments reported to CMS, 2019-2025
36 companies · $1,866 in 2025
The $1,866 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $216 · 2021: $846 · 2022: $1,264 · 2023: $1,564 · 2024: $1,505 · 2025: $1,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,934.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,703.33 | 2019-2025 | Cardiomems, Amplatzer Talisman, Triclip |
| Medtronic, INC. | $1,044.23 | 2021-2025 | Micra, Linq II, Symplicity G3 |
| Edwards Lifesciences Corporation | $851.48 | 2020-2025 | Mitris Resilia Mitral Valve, Sapien 3 Ultra Resilia |
| Amgen INC. | $412.63 | 2019-2025 | Repatha |
| Esperion Therapeutics, INC. | $393.01 | 2021-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $364.66 | 2022-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $351.69 | 2019-2025 | Watchman Flx, Watchman Access System |
| Merck Sharp & Dohme LLC | $266.45 | 2024-2025 | Verquvo, Winrevair |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.31 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $225.64 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $216.29 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $210.45 | 2020-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $189.27 | 2021-2025 | Opsumit, Uptravi |
| United Therapeutics Corporation | $174.59 | 2023-2025 | Tyvaso, Tyvaso, Orenitram |
| Atricure, INC. | $144.76 | 2025 | Synergy Ablation System, Atriclip Laa Exclusion System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $117.05 | 2019-2025 | |
| Abiomed | $86.80 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $85.36 | 2023-2025 | Farxiga, Wainua |
| Bayer Healthcare Pharmaceuticals INC. | $85.08 | 2023-2024 | |
| Impulse Dynamics (USA) INC. | $65.87 | 2022-2023 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $65.67 | 2022-2024 | Evkeeza |
| Heartflow, INC. | $65.37 | 2023-2025 | Ffrct |
| Astellas Pharma US INC | $50.65 | 2019-2021 | |
| Irhythm Technologies, INC. | $45.34 | 2019-2022 | |
| Preventice Services, LLC | $41.67 | 2021 | |
| Alnylam Pharmaceuticals INC. | $38.73 | 2024-2025 | Amvuttra |
| Bridgebio Pharma, INC. | $35.90 | 2025 | Attruby |
| Sanofi-Aventis U.S. LLC | $35.53 | 2023-2024 | |
| Philips North America LLC | $29.99 | 2025 | Mcot |
| Lantheus Medical Imaging, INC. | $28.34 | 2023 | Definity |
| Kiniksa Pharmaceuticals, LTD. | $24.79 | 2023 | Arcalyst |
| Terumo Medical Corporation | $24.47 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $23.48 | 2024 | |
| Scpharmaceuticals INC. | $22.23 | 2025 | |
| Kestra Medical Technology Services, INC. | $20.77 | 2024 | Assure Wcd |
| Lilly USA, LLC | $19.81 | 2025 | Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomas Vasiliauskas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.